Recent Advances in Virus-Like Particle-Based Vaccines
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Attenuated/Inactivated/Live and Vectored Vaccines".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 45
Special Issue Editor
Special Issue Information
Dear Colleagues,
The first virus-like particle (VLP)-based vaccine, designed to combat the hepatitis B virus, marks a significant milestone in subunit vaccine development. Among the notable examples of VLPs successfully employed as human and animal health immunizing agents are the vaccines for human papillomavirus and porcine circovirus type 2. Beyond their role as vaccines, VLPs have the potential to function as scaffolds for the incorporation of short peptides and antigens, thereby enhancing their delivery system. This targeted approach allows for a focused strategy to concentrate on one or a select few antigens instead of overwhelming the immune response with a myriad of antigens. Moreover, VLPs can be strategically utilized to induce immune tolerance or robust immune responses against antigens that are over-expressed in cancer cells, presenting new avenues for cancer immunotherapy.
In this Special Issue, we invite research articles and reviews that delve into these promising developments. Research areas of interest include, but are not limited to, the following:
- VLP Design and Antigen Engineering;
- Immune Response and Vaccine Delivery;
- Preclinical and Clinical Evaluation;
- Therapeutic Vaccines for Chronic Diseases;
- Rapid Vaccine Development for Emerging Pathogens.
I look forward to receiving your contributions.
Dr. Abel Gutiérrez-Ortega
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- virus-like particles (VLPs)
- vaccine design
- immune response mechanisms
- clinical trials
- therapeutic vaccines
- vaccine manufacturing
- antigen delivery
- rapid vaccine development
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
